论文部分内容阅读
药明康德合作伙伴卫材株式会社宣布,其自主发现和开发的抗癌药物产品Lenvima在3期临床试验中与索拉非尼比较,一线治疗不可切除的肝细胞癌患者达到了研究主要终点。肝癌是癌症死亡的第二大原因,据估计每年全世界范围约有80万个新增病例,也造成每年约70万的死亡人数。肝细胞癌占原发性肝癌病例的85%~90%。肝细胞癌与慢性肝病,特别是肝硬化有关。肝硬化的主要原因是乙型肝炎病毒和丙型肝炎病毒。目前,手术是该疾病治疗的首项选择。
WuXi, a partner of WuXi PharmaTech, announced that its self-discovered and developed anticancer drug product Lenvima compared with sorafenib in phase 3 clinical trials, the first-line treatment of unresectable hepatocellular carcinoma patients reached the primary endpoint of the study. Liver cancer is the second leading cause of cancer death. It is estimated that there are about 800,000 new cases worldwide each year, and it also causes about 700,000 deaths each year. Hepatocellular carcinoma accounts for 85% to 90% of primary liver cancer cases. Hepatocellular carcinoma is associated with chronic liver disease, especially cirrhosis. The main causes of cirrhosis are hepatitis B virus and hepatitis C virus. Currently, surgery is the first choice for the treatment of the disease.